Abstract:BackgroundHigh-field intraoperative magnetic resonance imaging (iMRI) has been studied in two single-centre randomised trials with patients who have glioblastoma and is hypothesised to enable a greater extent of tumour resection and prolong survival in patients with gliomas. iMRI for glioblastomas has also been shown to be significantly superior to 5-ALA and white-light surgery. However, the real value of iMRI is still a controversial issue. Given that use of this technology is relatively expensive, a high-quality prospective randomised trial is necessary before the approach can be made widely available. We have undertaken a single-centre prospective, randomised controlled trial to assess the clinical efficacy of 3.0T iMRI-guided resection of malignant gliomas compared with conventional neuronavigation only. Here we present the interim analysis of a long-term follow-up of patients with high-grade gliomas.MethodsEligible patients were aged 18–70 years with suspected (as assessed by consaltant surgeon), newly diagnosed malignant supratentorial glioma, met the Karnofsky performance scale 70 or above, and for whom gross total resection was intended. Patients were excluded if they had: tumour of the midline, basal ganglia, cerebellum, or brain stem; MRI contraindications; inability to give informed consent; renal or hepatic insufficiency; history of malignant tumours of other systems; or pathology other than astrocytoma, oligodendroglioma, or oligoastoryctoma (WHO grade II to IV). All participants were randomly assigned to either the trial group (iMRI group) or control group (conventional neuronavigation group) after giving written consent. All surgical protocols including conventional neuro-navigation are identical between the two groups; iMRI is specifically used in the trial group. The estimated sample size was 303 patients in the intent-to-treat analysis to give 80% complete power with a type I error of 0·05. Computational randomisation was done when maximal safe resection was achieved by the masked surgeons. The primary endpoint was extent of tumour resection. The secondary endpoints were progression-free survival and overall survival. This trial is registered with ClinicalTrial.gov, number NCT01479686. This study was approved by the Huashan Institutional Review Board. Written informed consents were given by patients or their attorneys before surgery.FindingsBetween March, 2012, and August, 2015, we enrolled 202 patients, 11 of whom were subsequently excluded because of unbefitting pathology. 177 patients were followed-up more than 6 months and subsequently analysed. 190 patients had low-grade gliomas (51 males vs 39 females, mean age 38·55 years [SD 9·56]), and 87 patients had high-grade gliomas (56 males vs 31 females, mean age 50·42 years [12·18). 43 of the patients with high-grade gliomas were enrolled in the iMRI group, and 44 patients with high-grade gliomas were enrolled in the control group. The extent of tumour resection (iMRI median 100% [IQR 70·87–100] vs control median 98·76% [51·81–100]) and the rate of gross total resection (86% vs 45%) were higher in the iMRI group than that in the control group (p<0·0001). Patients in the iMRI group who had eloquent high-grade gliomas had significantly longer progression-free survival (median not reached vs 13·2 months, p=0·012) and overall survival (median not reached vs 21·5 months, p=0·003) than patients in the control group. No events were identified as side-effects of iMRI.InterpretationThe results address hypotheses about the clinical benefits of 3.0T iMRI-guided maximal safe resection of glioma. It is practical to increase the extent of tumour resection for high-grade gliomas to prolong progression-free survival and overall survival, especially for eloquent high-grade gliomas.FundingNational Key Technology R&D Program of China (No. 2014BAI04B05) and the Shanghai Municipal Health Bureau (XBR2011022).

Threshold Analysis of Extent of Resection for Patients with Grade IIIgliomas Using MRI

A Multivariate Analysis of the Prognostic Factors of Grade III Gliomas

Relationship between the extent of resection and the survival of patients with low-grade gliomas: a systematic review and meta-analysis

Effect of High-field iMRI Guided Resection in Cerebral Glioma Surgery: A Randomized Clinical Trial

Prognostic factors for patients with glioma located in brain eloquent areas

Application of Delta T1 maps for quantitative and objective assessment of extent of resection and survival prediction in glioblastoma

Potential and Pitfalls of Postoperative Volumetric Assessment of Extent of Resection in High-Grade Glioma in Resource-Constrained Settings

The factors effecting on the prognosis of WHO grade Ⅲ glioma

Nimg-35. Impact Of Resection At Time Of First Recurrence In Who Grade 2 Idh-Mutant Gliomas

Quantitative Analysis of Permeability for Glioma Grading Using Dynamic Contrast-Enhanced Magnetic Resonance Imaging

Application of 3.0 T Intraoperative MRI in Glioma Surgery

Efficacy and Toxicity of Different Target Volume Delineations of Radiotherapy Based on the Updated RTOG/NRG and EORTC Guidelines in Patients with High Grade Glioma: A Randomized, Controlled Clinical Trial.

Prognostic Implications of Epidermal Growth Factor Receptor Variant III Expression and Nuclear Translocation in Chinese Human Gliomas

142 3.0T Imri Guided Resection in Cerebral Glioma Surgery

Analysis of Prognostic Factors of World Health Organization Grade III Meningiomas

Extent of Resection Thresholds in Molecular Subgroups of IDH-Wildtype Glioblastoma

3.0T Imri-Guided Resection of Eloquent High-Grade Gliomas: Preliminary Results of A Randomised Controlled Trial

Peritumor Edema Serves as an Independent Predictive Factor of Recurrence Patterns and Recurrence-Free Survival for High-Grade Glioma

The Prognostic Role of Volumetric MRI Evaluation in the Surgical Treatment of Glioblastoma

Quantitative Analysis of Neovascular Permeability in Glioma by Dynamic Contrast-Enhanced MR Imaging

Extent of Resection in Meningioma: Predictive Factors and Clinical Implications